Cosentyx in Asia-Pacific: Transforming Psoriasis & Arthritis

“The Asia-Pacific secukinumab market is on the verge of notable growth, primarily fueled by the rising incidence of autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Several key factors are driving this expansion, such as increasing healthcare expenditures, improved access to advanced biologic therapies, and heightened awareness of autoimmune conditions among both healthcare professionals and patients. Ongoing research and development initiatives, along with increased governmental support, further enhance the market's potential. Secukinumab, known commercially as Cosentyx by Novartis, has proven its efficacy and safety in real-world applications across Asia-Pacific populations, leading to greater adoption among healthcare providers.

Despite the promising outlook, the market faces challenges, particularly high treatment costs and varying levels of awareness in different regions. These barriers could hinder the rate of adoption and growth. However, the continuous advancements in healthcare infrastructure and a stronger focus on managing autoimmune diseases present opportunities for the market to thrive. As healthcare systems evolve and the emphasis on effective treatment options grows, the Asia-Pacific secukinumab market is projected to experience substantial growth in the coming years, positively impacting patients' lives and expanding the reach of innovative therapies."

The Asia Pacific Secukinumab market was valued at USD 1,233 Million in 2023 and is projected to reach USD xx Billion by 2030, with a compound annual growth rate (CAGR) of 5.3% from 2024 to 2030.

Additionally, the region's healthcare system is getting better, which makes it simpler for patients to get cutting-edge therapies like secukinumab. Innovative medicines are becoming more accessible as earnings grow and more people join the middle class, enabling more patients to benefit from them.

Patients should anticipate prompt and efficient treatments because nations like China, India, Japan, and Australia are making significant investments in healthcare. Even though there are still obstacles to overcome, like disparities in healthcare access and pricing throughout the area, Asia-Pacific is becoming one of the secukinumab markets with the quickest rate of growth due to rising health awareness and the growing acceptance of biologic medicines.

Significant investments in healthcare systems across Asia-Pacific enhance access to advanced therapies, including biologics.

Many countries in the Asia-Pacific region are investing heavily in their healthcare infrastructure to meet the growing demand for modern medical treatments. For instance, Japan, China, and India are expanding healthcare facilities, modernizing hospitals, and increasing the availability of advanced medical technologies. This includes improving access to biologic therapies, such as secukinumab.

As healthcare systems enhance, patients gain greater access to specialized treatments, which helps reduce barriers to care for autoimmune diseases. In rapidly developing economies like India and China, improvements in healthcare infrastructure are accompanied by government efforts to extend medical services to rural and underserved areas, ensuring that even remote populations can access advanced biologic treatments.

Economic growth and higher disposable incomes enable more patients to afford high-cost biologic treatments like secukinumab.

Economic growth in the Asia-Pacific region has significantly boosted disposable incomes, especially in emerging economies such as China and India. This economic expansion has enabled more people to afford expensive treatments, particularly biologics, which were previously out of reach for many due to high out-of-pocket costs. As the middle class continues to grow, healthcare consumers are increasingly willing to invest in these costly medications, often viewed as superior treatment options for managing chronic diseases. Moreover, private health insurance and employer-provided healthcare plans are becoming more widespread, offering better coverage for expensive therapies like secukinumab. With a larger segment of the population able to afford such treatments, the demand for biologics continues to rise, further driving the growth of the secukinumab market in the region.

Increased awareness of biologics' effectiveness is leading to higher adoption of secukinumab.

In recent years, there has been a notable increase in awareness of autoimmune diseases and the availability of biologic treatments in the Asia-Pacific region. This growth has been primarily fueled by educational campaigns, media coverage, and advocacy from healthcare professionals and patient groups. As a result, patients are becoming more informed about their treatment options, with many actively seeking biologics like secukinumab due to their proven effectiveness in managing chronic autoimmune conditions.

This shift in patient preferences is influencing how healthcare providers approach treatment, leading to a greater emphasis on biologics rather than traditional therapies. Additionally, as more patients opt for biologics to achieve better health outcomes, healthcare systems are facing increased pressure to ensure these therapies are available and affordable, which is further contributing to market growth.

Healthcare reforms and government initiatives are expanding access to biologic treatments across the region.

Governments throughout the Asia-Pacific region are making genuine efforts to improve healthcare access, especially for advanced treatments like biologics. For instance, Japan and South Korea have established national insurance systems that cover a wider range of treatments, allowing more patients to benefit from biologic therapies. In India and China, the focus is on reducing medication costs and improving reimbursement policies, which helps even more patients gain access to these vital treatments.

Also, several countries are working on regulatory changes to speed up the approval process for new biologic drugs, ensuring they reach patients more quickly. These initiatives not only make it easier for people to access treatments like secukinumab but also contribute to a healthcare system that supports those with chronic autoimmune diseases, giving them the timely care they need to lead healthier lives.

Pharmaceutical companies are increasing their presence in the region, enhancing the availability and distribution of secukinumab.

Pharmaceutical companies are increasingly focusing their efforts in the Asia-Pacific region by ramping up investments in marketing and distribution, and by forming partnerships with local businesses. For instance, the manufacturer of secukinumab has teamed up with regional distributors and set up local production facilities. This not only makes the drug more available but also helps to lower costs for patients.

As these companies grow their presence in the region, they're better positioned to respond to the rising demand for biologic therapies. This expanded competition could lead to lower prices for treatments like secukinumab, which would make them more affordable for a larger number of patients. Plus, working with local partners allows these companies to navigate the often complex regulatory requirements more smoothly. All of this means that more patients can benefit from the therapeutic effects of secukinumab and similar biologics, marking a significant step forward in healthcare access in the Asia-Pacific area.

Competitive Landscape

Some of the major companies operating within the Secukinumab market are:  Novartis.